We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+36.02%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$334M
AUM Growth
+$107M
(+47%)
Cap. Flow
+$48M
Cap. Flow
% of AUM
14.36%
Top 10 Holdings %
Top 10 Hldgs %
34.01%
Holding
80
New
29
Increased
13
Reduced
13
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LHCG
LHC Group LLC
LHCG
|
+$11M |
| 2 |
Charles River Laboratories
CRL
|
+$8.78M |
| 3 |
Cencora
COR
|
+$8.29M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
+$7.23M |
| 5 |
Molina Healthcare
MOH
|
+$6.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$10.4M |
| 2 |
Centene
CNC
|
+$10.1M |
| 3 |
Encompass Health
EHC
|
+$7.36M |
| 4 |
MASI
Masimo
MASI
|
+$6.2M |
| 5 |
Novartis
NVS
|
+$5.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.88% |
| 2 | Energy | 6.53% |
| 3 | Technology | 0.84% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMRN
51
Amarin Corp
AMRN
$296M
| $2.42M | 0.73% |
+17,500
| New | +$2.41M |
|
52
Fate Therapeutics
FATE
$319M
| $2.4M | 0.72% |
70,000
-25,000
| -26% | -$745K |
|
53
MacroGenics
MGNX
$249M
| $1.95M | 0.59% |
+70,000
| New | +$1.22M |
|
|
ONC
54
BeOne Medicines Ltd
ONC
$40.6B
| $1.88M | 0.56% |
+10,000
| New | +$1.63M |
|
|
WBA
55
DELISTED
Walgreens Boots Alliance
WBA
| $1.7M | 0.51% |
40,000
-40,000
| -50% | -$1.7M |
|
56
PTC Therapeutics
PTCT
$6.15B
| $1.52M | 0.46% |
+30,000
| New | +$1.47M |
|
|
GNMK
57
DELISTED
GenMark Diagnostics, Inc
GNMK
| $1.47M | 0.44% |
+100,000
| New | +$1.02M |
|
58
Karyopharm Therapeutics
KPTI
$47.6M
| $1.42M | 0.43% |
5,000
-1,667
| -25% | -$493K |
|
59
Incyte
INCY
$24.5B
| $1.04M | 0.31% |
+10,000
| New | +$964K |
|
|
BMY.RT
60
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $537K | 0.16% |
150,000
-300,000
| -67% | -$1.08M |
|
|
AKRO
61
DELISTED
Akero Therapeutics
AKRO
| – | – |
-60,000
| Closed | -$1.27M |
|
62
Alkermes
ALKS
$8.26B
| – | – |
-150,000
| Closed | -$2.16M |
|
|
AMRN
63
CALL
Amarin Corp
AMRN
$296M
| – | – |
-10,000
| Closed | -$800K |
|
64
Arvinas
ARVN
$588M
| – | – |
-40,000
| Closed | -$1.61M |
|
65
Becton Dickinson
BDX
$49.4B
| – | – |
-25,625
| Closed | -$5.74M |
|
66
Boston Scientific
BSX
$74.2B
| – | – |
-125,000
| Closed | -$4.08M |
|
67
Chewy
CHWY
$9.2B
| – | – |
-100,000
| Closed | -$3.75M |
|
|
68
Centene
CNC
$32.1B
| – | – |
-170,000
| Closed | -$10.1M |
|
|
69
Encompass Health
EHC
$12.4B
| – | – |
-144,555
| Closed | -$7.36M |
|
70
CALL
Exelixis
EXEL
$12.7B
| – | – |
-100,000
| Closed | -$1.72M |
|
71
Intuitive Surgical
ISRG
$142B
| – | – |
-21,000
| Closed | -$3.47M |
|
|
MASI
72
DELISTED
Masimo
MASI
| – | – |
-35,000
| Closed | -$6.2M |
|
|
73
Medtronic
MDT
$116B
| – | – |
-115,000
| Closed | -$10.4M |
|
74
Minerva Neurosciences
NERV
$206M
| – | – |
-31,250
| Closed | -$1.5M |
|
|
NVO
75
Novo Nordisk
NVO
$207B
| – | – |
-110,000
| Closed | -$3.31M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q2 2020 Portfolio in Review
As of Q2 2020, Integral Health Asset Management held 80 positions worth $334M, up 47% from $227M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Integral Health Asset Management deployed $48M of net new capital in Q2 2020, opening 29 new positions and adding to 13 existing holdings. Its largest new stake was Charles River Laboratories: 55,000 shares worth $9.59M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Energy and Technology.
On the sell side, the largest reduction was Merck, an estimated $4.34M trimmed.
- Integral Health Asset Management's largest Q2 2020 buy was Charles River Laboratories: 55,000 shares worth $9.59M.
- Integral Health Asset Management added most to LHC Group LLC in Q2 2020, an estimated $11M increase.
- Integral Health Asset Management's biggest Q2 2020 reduction was Merck, cutting an estimated $4.34M.
- Integral Health Asset Management fully exited Medtronic in Q2 2020, selling an estimated $10.4M.
- Integral Health Asset Management's ten largest holdings make up 34% of its $334M portfolio in Q2 2020.
- Integral Health Asset Management opened 29 new positions and closed 20 in Q2 2020.
- Integral Health Asset Management's portfolio value rose 47% quarter-over-quarter to $334M.
Based on Integral Health Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.